{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:28:24Z","timestamp":1791340104085,"version":"4.3.1"},"reference-count":40,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>An acquired somatic mutation in the JAK2 gene (JAK2-V617F) is present in the majority of patients with myeloproliferative disorders (MPDs). Several phenotypic manifestations (polycythemia vera [PV], essential thrombocythemia [ET], and primary myelofibrosis) can be associated with the same mutation. We generated JAK2-V617F transgenic mice using a human JAK2 gene with the sequences encoding the kinase domain placed in the inverse orientation and flanked by antiparallel loxP sites. Crossing mice of one transgenic line (FF1) with transgenic mice expressing Cre-recombinase under the control of the hematopoiesis specific Vav promoter led to expression of JAK2-V617F that was lower than the endogenous wild-type Jak2. These mice developed a phenotype resembling ET with strongly elevated platelet counts and moderate neutrophilia. Induction of the JAK2-V617F transgene with the interferon-inducible MxCre resulted in expression of JAK2-V617F approximately equal to wild-type Jak2 and a PV-like phenotype with increased hemoglobin, thrombocytosis, and neutrophilia. Higher levels of JAK2-V617F in mouse bone marrow by retroviral transduction caused a PV-like phenotype without thrombocytosis. These data are consistent with the hypothesis that the ratio of mutant to wild-type JAK2 is critical for the phenotypic manifestation. A similar correlation was also found in patients with MPD.<\/jats:p>","DOI":"10.1182\/blood-2007-08-107748","type":"journal-article","created":{"date-parts":[[2007,12,26]],"date-time":"2007-12-26T20:44:33Z","timestamp":1198701873000},"page":"3931-3940","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":399,"title":["Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice"],"prefix":"10.1182","volume":"111","author":[{"given":"Ralph","family":"Tiedt","sequence":"first","affiliation":[{"name":"Department of Research, Experimental Hematology, University Hospital Basel, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Hao-Shen","sequence":"additional","affiliation":[{"name":"Department of Research, Experimental Hematology, University Hospital Basel, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta A.","family":"Sobas","sequence":"additional","affiliation":[{"name":"Department of Research, Experimental Hematology, University Hospital Basel, Basel, Switzerland;"},{"name":"Servicio de Hematologia y Hemoterapia, Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Looser","sequence":"additional","affiliation":[{"name":"Department of Research, Experimental Hematology, University Hospital Basel, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Dirnhofer","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital Basel, Basel, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrg","family":"Schwaller","sequence":"additional","affiliation":[{"name":"Department of Research, Childhood Leukemia, University Hospital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radek C.","family":"Skoda","sequence":"additional","affiliation":[{"name":"Department of Research, Experimental Hematology, University Hospital Basel, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111713034765300_B1","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"2019111713034765300_B2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"2019111713034765300_B3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"2019111713034765300_B4","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders.","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"2019111713034765300_B5","first-page":"871","article-title":"Gain of function, loss of control\u2013a molecular basis for chronic myeloproliferative disorders.","volume":"90","author":"Cazzola","year":"2005","journal-title":"Haematologica"},{"key":"2019111713034765300_B6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0301-472X(01)00789-5","article-title":"Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera.","volume":"30","author":"Kralovics","year":"2002","journal-title":"Exp Hematol"},{"key":"2019111713034765300_B7","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2006-02-002030","article-title":"JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.","volume":"108","author":"Lacout","year":"2006","journal-title":"Blood"},{"key":"2019111713034765300_B8","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1182\/blood-2005-12-4824","article-title":"Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.","volume":"107","author":"Wernig","year":"2006","journal-title":"Blood"},{"key":"2019111713034765300_B9","doi-asserted-by":"crossref","first-page":"11156","DOI":"10.1158\/0008-5472.CAN-06-2210","article-title":"Characterization of murine JAK2V617F-positive myeloproliferative disease.","volume":"66","author":"Bumm","year":"2006","journal-title":"Cancer Res"},{"key":"2019111713034765300_B10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1371\/journal.pone.0000018","article-title":"Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.","volume":"1","author":"Zaleskas","year":"2006","journal-title":"PLoS ONE"},{"key":"2019111713034765300_B11","first-page":"106","article-title":"Molecular pathogenesis of polycythemia induced in mice by JAK2 V617F.","author":"Zaleskas","year":"2005","journal-title":"Blood"},{"key":"2019111713034765300_B12","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1128\/MCB.20.2.507-515.2000","article-title":"Role of the distal half of the c-Mpl intracellular domain in control of platelet production by thrombopoietin in vivo.","volume":"20","author":"Luoh","year":"2000","journal-title":"Mol Cell Biol"},{"key":"2019111713034765300_B13","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1006\/geno.2000.6451","article-title":"A highly efficient Escherichia coli-based chromosome engineering system adapted for recombinogenic targeting and subcloning of BAC DNA.","volume":"73","author":"Lee","year":"2001","journal-title":"Genomics"},{"key":"2019111713034765300_B14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/nar\/gnf089","article-title":"Cre recombinase-mediated inversion using lox66 and lox71: method to introduce conditional point mutations into the CREB-binding protein.","volume":"30","author":"Zhang","year":"2002","journal-title":"Nucleic Acids Res"},{"key":"2019111713034765300_B15","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1093\/emboj\/17.18.5321","article-title":"Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL\/JAK2 fusion genes.","volume":"17","author":"Schwaller","year":"1998","journal-title":"Embo J"},{"key":"2019111713034765300_B16","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","article-title":"Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u201creal-time\u201d quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)\u2013a Europe against cancer program.","volume":"17","author":"Beillard","year":"2003","journal-title":"Leukemia"},{"key":"2019111713034765300_B17","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1182\/blood-2006-01-013540","article-title":"The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera.","volume":"108","author":"Lippert","year":"2006","journal-title":"Blood"},{"key":"2019111713034765300_B18","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1182\/blood-2005-11-009605","article-title":"Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.","volume":"108","author":"Kralovics","year":"2006","journal-title":"Blood"},{"key":"2019111713034765300_B19","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1182\/blood-2003-03-0744","article-title":"Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders.","volume":"102","author":"Kralovics","year":"2003","journal-title":"Blood"},{"key":"2019111713034765300_B20","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/immu.200310005","article-title":"Transgenic mice with hematopoietic and lymphoid specific expression of Cre.","volume":"33","author":"de Boer","year":"2003","journal-title":"Eur J Immunol"},{"key":"2019111713034765300_B21","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1126\/science.7660125","article-title":"Inducible gene targeting in mice.","volume":"269","author":"Kuhn","year":"1995","journal-title":"Science"},{"key":"2019111713034765300_B22","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1182\/blood-2005-05-1871","article-title":"TGF-beta type II receptor-deficient thymocytes develop normally but demonstrate increased CD8+ proliferation in vivo.","volume":"106","author":"Leveen","year":"2005","journal-title":"Blood"},{"key":"2019111713034765300_B23","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1365-2141.1992.tb02999.x","article-title":"Serum erythropoietin in the diagnosis of polycythaemia and after phlebotomy treatment.","volume":"81","author":"Birgegard","year":"1992","journal-title":"Br J Haematol"},{"key":"2019111713034765300_B24","first-page":"1194","article-title":"Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis.","volume":"89","author":"Mossuz","year":"2004","journal-title":"Haematologica"},{"key":"2019111713034765300_B25","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia.","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"key":"2019111713034765300_B26","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2006-10-054940","article-title":"The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera.","volume":"110","author":"Dupont","year":"2007","journal-title":"Blood"},{"key":"2019111713034765300_B27","doi-asserted-by":"crossref","first-page":"27251","DOI":"10.1074\/jbc.M501376200","article-title":"Janus kinases affect thrombopoietin receptor cell surface localization and stability.","volume":"280","author":"Royer","year":"2005","journal-title":"J Biol Chem"},{"key":"2019111713034765300_B28","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1182\/blood.V90.10.4031","article-title":"Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia.","volume":"90","author":"Horikawa","year":"1997","journal-title":"Blood"},{"key":"2019111713034765300_B29","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1056\/NEJM199802263380903","article-title":"Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera.","volume":"338","author":"Moliterno","year":"1998","journal-title":"N Engl J Med"},{"key":"2019111713034765300_B30","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1182\/blood.V94.8.2555.420k14_2555_2561","article-title":"Posttranslational processing of the thrombopoietin receptor is impaired in polycythemia vera.","volume":"94","author":"Moliterno","year":"1999","journal-title":"Blood"},{"key":"2019111713034765300_B31","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1182\/blood-2006-03-008805","article-title":"Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression.","volume":"108","author":"Moliterno","year":"2006","journal-title":"Blood"},{"key":"2019111713034765300_B32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1023\/A:1008918913249","article-title":"Size matters: use of YACs, BACs and PACs in transgenic animals.","volume":"10","author":"Giraldo","year":"2001","journal-title":"Transgenic Res"},{"key":"2019111713034765300_B33","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/gene.1078","article-title":"A CamKIIalpha iCre BAC allows brain-specific gene inactivation.","volume":"31","author":"Casanova","year":"2001","journal-title":"Genesis"},{"key":"2019111713034765300_B34","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/gene.20062","article-title":"Highly restricted expression of Cre recombinase in cerebellar Purkinje cells.","volume":"40","author":"Zhang","year":"2004","journal-title":"Genesis"},{"key":"2019111713034765300_B35","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.V94.6.1855","article-title":"Promoter elements of vav drive transgene expression in vivo throughout the hematopoietic compartment.","volume":"94","author":"Ogilvy","year":"1999","journal-title":"Blood"},{"key":"2019111713034765300_B36","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.exphem.2004.01.005","article-title":"Regulatory elements of the vav gene drive transgene expression in hematopoietic stem cells from adult mice.","volume":"32","author":"Almarza","year":"2004","journal-title":"Exp Hematol"},{"key":"2019111713034765300_B37","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood-2005-09-3826","article-title":"Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.","volume":"107","author":"Passamonti","year":"2006","journal-title":"Blood"},{"key":"2019111713034765300_B38","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1182\/blood-2006-04-018259","article-title":"Progenitors homozygous for the V617F JAK2 mutation occur in most patients with polycythemia vera, but not essential thrombocythemia.","volume":"108","author":"Scott","year":"2006","journal-title":"Blood"},{"key":"2019111713034765300_B39","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"key":"2019111713034765300_B40","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1182\/blood-2007-07-101576","article-title":"Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders.","volume":"111","author":"Pietra","year":"2008","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/111\/8\/3931\/1301155\/zh800808003931.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/111\/8\/3931\/1301155\/zh800808003931.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T13:04:05Z","timestamp":1573995845000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/111\/8\/3931\/24612\/Ratio-of-mutant-JAK2V617F-to-wildtype-Jak2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,15]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,4,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2007-08-107748","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,15]]}}}